Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Berlin Institute for Urologic Research, Berlin, Germany.
Cancer Biomark. 2021;30(4):381-393. doi: 10.3233/CBM-201600.
There is an urgent need for better prostate cancer (PCa) biomarkers due to the low specificity of prostate specific antigen (PSA).
Prostate Health Index (PHI) is an advanced PSA-based test for early detection of PCa. The present study aim was to investigate the potential improvement of diagnostic accuracy of PHI by its combination with suitable discriminative microRNAs (miRNAs).
A two-phase study was performed. In a discovery phase, a panel of 177 miRNAs was measured in ten men with biopsy proven PCa and ten men with histologically no evidence of malignancy (NEM). These results were validated in a second phase including 25 patients in each group. The patients of all groups were matched regarding their PSA values and PHI were measured.
Based on data in the discovery phase, four elevated miRNAs were selected as potential miRNA candidates for further validation. A combination of miR-222-3p as the best discriminative miRNA with PHI extended the diagnostic accuracy of PHI from an AUC value of 0.690 to 0.787 and resulted in a sensitivity of 72.0% and a specificity of 84.0%.
Circulating microRNAs show useful diagnostic potential in combination with common used biomarkers to enhance their diagnostic power.
由于前列腺特异性抗原（PSA）的特异性低，因此迫切需要更好的前列腺癌（PCa）生物标志物。
前列腺健康指数（PHI）是一种基于 PSA 的先进测试，用于早期发现 PCa。本研究旨在通过将其与合适的鉴别性微小 RNA（miRNA）结合，来研究 PHI 诊断准确性的潜在提高。
进行了两阶段研究。在发现阶段，对 10 名经活检证实患有 PCa 的男性和 10 名组织学上无恶性肿瘤证据（NEM）的男性进行了 177 种 miRNA 的检测。在包括 25 名患者的第二阶段对这些结果进行了验证。所有组的患者均根据其 PSA 值进行匹配，并测量了 PHI。
基于发现阶段的数据，选择了四个升高的 miRNA 作为进一步验证的潜在 miRNA 候选物。将 miR-222-3p 与 PHI 结合作为最佳鉴别性 miRNA ，将 PHI 的诊断准确性从 AUC 值 0.690 扩展到 0.787，灵敏度为 72.0％，特异性为 84.0％。
循环 microRNAs 与常用的生物标志物结合显示出有用的诊断潜力，可以增强其诊断能力。
